Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04608786
Recruitment Status : Enrolling by invitation
First Posted : October 29, 2020
Last Update Posted : January 11, 2022
Sponsor:
Information provided by (Responsible Party):
Lee's Pharmaceutical Limited

Brief Summary:
This is a Phase Ib, open-label,single-arm, clinical study, aiming to investigate the safety, tolerability and pharmacokinetics of ZKAB001 (a fully human monoclonal antibody targeting the Programmed Death - Ligand 1 (PD-L1) membrane receptor ) combined with capecitabine as adjuvant chemotherapy for patients with biliary tract cancers after radical resection.After completing 8 courses of combined treatment ,ZKAB001 was continued to be administered separately once 3 weeks for a total of 16 cycles or 1 year.

Condition or disease Intervention/treatment Phase
Biliary Tract Cancer Drug: ZKAB001 5mg/kg Drug: Capecitabine Phase 1

Detailed Description:
This study includes two phases,the first phase is the dose exploration, 6 subjects were first included at the initial dose to confirm the dose safety. If the toxicity is not tolerated, the dose of the chemotherapeutic agent will be reduced depending on the toxicity(including hematological toxicity and non-hematological toxicity) for further exploration. If it can be tolerated, the recommended dose is determined and expanded on this dose. the second phase is the dose expansion, 4 subjects will be enrolled to further observe the safety and efficacy. The DLT(Dose limited toxicity) observation period is set as the first course of treatment(3 weeks). The end point is that the patient has been taking the drug for 16 cycles or 1 year, or the patient dies or develops intolerable toxicity or confirmed disease recurrence or distant metastasis or withdrawal of informed consent.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single-arm, Open-label,Phase Ib Clinical Study of ZKAB001 Combined With Capecitabine in Adjuvant Therapy for Patients With Biliary Tract Cancer After Radical Resection
Actual Study Start Date : February 1, 2021
Estimated Primary Completion Date : December 1, 2022
Estimated Study Completion Date : December 1, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Combined the therapy using Capecitabine and PD-L1
PD-L1 antibody ZKAB001 D1 5mg/kg every three weeks,up to 16 cycles or 1 year of treatment or the patient has tumor recurrence or metastasis Capecitabine 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses, or the patient has tumor recurrence or metastasis
Drug: ZKAB001 5mg/kg
ZKAB001 D1 IV 5mg/kg every three weeks,up to 16 cycles or 1 year
Other Name: PD-L1 monoclonal antibody

Drug: Capecitabine
Capecitabine po 1000mg / m2/time, 2 times/d for 2 weeks, followed by 1 week of stopping ,three weeks is a course of treatment with a total of 8 courses




Primary Outcome Measures :
  1. Dose limiting toxicity (DLT) [ Time Frame: 21 days after first dose ]
    Adverse events of level 3 or above related to the study drug occurring within 21 days after the first dose as assessed by CTCAE v5.0.

  2. Recommended phase II dose (RP2D) [ Time Frame: 21 days after first dose ]
    DLT occurs in no more than 1/6 subjects, this dose is defined as RP2D.


Secondary Outcome Measures :
  1. AUC(0-t) [ Time Frame: 16 periods or 1 year ]
    Area under curve 0-t

  2. Cmax [ Time Frame: 16 periods or 1 year ]
    Peak concentration

  3. Tmax [ Time Frame: 16 periods or 1 year ]
    Peak time

  4. Disease-free Survival [ Time Frame: up to 24 months ]
    Form date of randominzation until the date of the first tumor recurrence/ometastasis or death of the subject due to any reason

  5. Overall survival (OS) [ Time Frame: up to 24 months ]
    From date of randomization until the date of death from any cause or the date of last follow-up whichever came first

  6. the number of subjects presenting detectable anti drug antibodies (ADAs) [ Time Frame: through study completion,an average of 1 year ]
    To evaluated the number of subjects presenting detectable anti drug antibodies (ADAs)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. both men and women, age ≥ 18 years old;
  2. A histopathological or cytological diagnosis of gallbladder cancer and extrahepatic cholangiocarcinoma after radical resection
  3. Postoperative pathological stage is T2-4 or N1 R0/R1 resection;
  4. No more than 12 weeks from radical resection;
  5. Eastern Cooperative Oncology Group(ECOG) performance status score 0-1;
  6. Estimated life expectancy >6 months;
  7. Biliary drainage is in good condition, no current infection ;
  8. Have not received radiotherapy, chemotherapy, or immunotherapy for the primary tumor;
  9. The function of important organs meets the following requirements:

(1) Blood routine test: absolute neutrophil count (ANC) ≥ 1.5×109/L, platelets ≥ 100×109/L, hemoglobin ≥100g/L; (2) Biochemical tests : ALT, AST ≤ 2.5×ULN; ALB≥ 35g/L;total bilirubin ≤3×ULN; serum creatinine ≤ 1.5×ULN, creatinine clearance rate ≥50 mL/min(Crockcroft-Gault formula); 10.Subjects voluntarily joined the study, signed an informed consent form, had good compliance, and cooperated with the follow-up.

Exclusion Criteria:

  1. Local recurrence or distant metastasis (including ascites or malignant pleural effusion);
  2. Severe cardiovascular disease, such as New York Heart Association (New York Heart Association, NYHA standard) heart failure above grade 2, unstable angina, unstable arrhythmia, or color photos of the heart suggest LVEF (left ventricular ejection fraction) )<50%;
  3. Known allergy or hypersensitivity to monoclonal antibodies or fluorouracil drugs or their analogues;
  4. Subjects with known, active or suspicious autoimmune diseases, who are in a stable state and do not require systemic immunosuppressive therapy can be included in the group;
  5. Subjects were treated with immunosuppressants or systemic or absorbable topical corticosteroids within 2 weeks before the first study to achieve immunosuppressive purposes (>10mg/day prednisone or equivalent dose) ;
  6. Suffered from other active malignancies within 5 years before the first administration of the study drug. Cured localized tumors, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, breast carcinoma in situ, etc. can be included in the group;
  7. Active viral hepatitis (such as hepatitis B, hepatitis C, unless antiviral treatment is given and the HBV or HCV viral load is below the minimum detection limit can be considered for inclusion), HIV positive or a known history of acquired immunodeficiency syndrome ;
  8. Any active infection that requires systemic anti-infective treatment occurs within 14 days before the first medication;
  9. Have active tuberculosis in the past 1 year, regardless of treatment;
  10. Live attenuated vaccines have been used within 28 days before screening;
  11. Subjects who have previously received allogeneic bone marrow transplantation or solid organ transplantation;
  12. Have received any other experimental drug treatment within 28 days before signing the ICF;
  13. People who have difficulty swallowing or have known drug absorption disorders;
  14. Women who are pregnant or breastfeeding;
  15. Subjects of childbearing age who refuse to use effective contraceptive measures;
  16. Situations that other researchers think are not suitable for inclusion. -

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04608786


Locations
Layout table for location information
China
Renji Hospital Affiliated to School of Medicine, Shanghai Jiaotong University
Shanghai, China
Sponsors and Collaborators
Lee's Pharmaceutical Limited
Layout table for additonal information
Responsible Party: Lee's Pharmaceutical Limited
ClinicalTrials.gov Identifier: NCT04608786    
Other Study ID Numbers: NTL-LEES-2019-01
First Posted: October 29, 2020    Key Record Dates
Last Update Posted: January 11, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Biliary Tract Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Biliary Tract Diseases
Digestive System Diseases
Capecitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents